Dose escalation for secondary loss of response in inflammatory bowel disease: 3-year outcomes and treatment persistence.
People on biologic therapy who lose response often face choices: switch drugs or increase dose. This study shows that escalating doses of infliximab, adalimumab, or vedolizumab frequently led to clinical improvement and...